Identification of the non-ribosomal peptide synthetase responsible for biosynthesis of the potential anti-cancer drug sansalvamide in Fusarium solani
Sansalvamide is a cyclic pentadepsipeptide produced by Fusarium solani and has shown promising results as potential anti-cancer drug. The biosynthetic pathway has until now remained unidentified, but here we used an Agrobacterium tumefaciens -mediated transformation (ATMT) approach to generate knock...
Gespeichert in:
Veröffentlicht in: | Current genetics 2016-11, Vol.62 (4), p.799-807 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Sansalvamide is a cyclic pentadepsipeptide produced by
Fusarium solani
and has shown promising results as potential anti-cancer drug. The biosynthetic pathway has until now remained unidentified, but here we used an
Agrobacterium tumefaciens
-mediated transformation (ATMT) approach to generate knockout mutants of two candidate non-ribosomal peptide synthetases (
NRPS29
and
NRPS30
). Comparative studies of secondary metabolites in the two deletion mutants and wild type confirmed the absence of sansalvamide in the
NRPS30
deletion mutant, implicating this synthetase in the biosynthetic pathway for sansalvamide. Sansalvamide is structurally related to the cyclic hexadepsipeptide destruxin, which both contain an α-hydroxyisocaproic acid (HICA) unit. A gene cluster responsible for destruxin production has previously been identified in
Metarhizium robertsii
together with a hypothetical biosynthetic pathway. Using comparative bioinformatic analyses of the catalytic domains in the destruxin and sansalvamide NRPSs, we were able to propose a model for sansalvamide biosynthesis. Orthologues of the gene clusters were also identified in species from several other genera including
Acremonium chrysogenum
and
Trichoderma virens
, which suggests that the ability to produce compounds related to destruxin and sansalvamide is widespread. |
---|---|
ISSN: | 0172-8083 1432-0983 |
DOI: | 10.1007/s00294-016-0584-4 |